FDA's approval of Sanofi and Regeneron Pharmaceuticals Inc.'s Praluent (alirocumab) and Amgen Inc.'s Repatha (evolocumab) a month apart was a fitting conclusion to the PCSK9 inhibitors' closely run race through late-stage clinical development and review.
Agency review documents show that many key milestones in the LDL-cholesterol-lowering drugs' development happened within months or weeks of each...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?